



Screening Allergy Questionnaire for Potential COVID-19 Vaccine Recipients

Primary screening (vaccine recipients):

1. **Have you had a prior allergic reaction, medications or otherwise?**
 - a. If no, proceed with vaccination and observe for 15 minutes
 - b. If yes, refer to the nurse, pharmacist, etc.
2. **Have you received the mRNA COVID-19 vaccine before?**
 - a. If no, proceed with vaccination and observe for 15 minutes
 - b. If yes, go to the next question
3. **Did you experience any severe reactions related to the vaccine?**
 - a. If no, proceed with vaccination and observe for 15 minutes
 - b. If yes, refer to the nurse, pharmacist, etc.

Secondary screening (nurse, pharmacist, or physician):

1. **If you had a prior allergic reaction, including anaphylaxis, what was the cause?**
 - a. If it was not related to a vaccine or injectable therapy, go to question 6
 - b. If it was related to a vaccine or injectable therapy, go to the next question
2. **Was the reaction related to a prior mRNA COVID-19 vaccine?**
 - a. If yes, defer vaccination and refer to an allergist
 - b. If yes but cleared by an allergist, proceed with vaccination and observe for 30 minutes
 - c. If no, go to the next question
3. **Was the reaction related to other vaccines or injectable therapy?**
 - a. If yes, defer vaccination and refer to an allergist
 - b. If no, go to the next question
4. **Is there documented hypersensitivity to polyethylene glycol (PEG) or polysorbate?**
 - a. If yes, defer vaccination and refer to an allergist. If unable to see an allergist, then **do not vaccinate**
 - b. If no, go to the next question
5. **Is there documented severe allergic reactions with any of the substances listed in Table 1?**
 - a. If yes, defer vaccination and refer to an allergist. If unable to see an allergist, then **do not vaccinate**
 - b. If no, proceed with vaccination and observe for 30 minutes
6. **What is the severity of the allergic reaction?**
 - a. If anaphylaxis, proceed with vaccination and observe for 30 minutes
 - b. If no anaphylaxis, proceed with vaccination and observe for 15 minutes

Table 1.

Description	Pfizer-BioNTech (mRNA)	Moderna (mRNA)	Janssen (viral vector)
Active ingredient	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2	Recombinant, replication-incompetent Ad26 vector, encoding a stabilized variant of the SARS-CoV-2 Spike (S) protein
Inactive ingredients	2[(polyethylene glycol (PEG))-2000]-N,N-ditetradecylacetamide	PEG2000-DMG: 1,2-dimyristoyl-rac-glycerol, methoxypolyethylene glycol	Polysorbate-80
	1,2-distearoyl-sn-glycero-3-phosphocholine	1,2-distearoyl-sn-glycero-3-phosphocholine	2-hydroxypropyl-β-cyclodextrin
	Cholesterol	Cholesterol	Citric acid monohydrate
	(4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)	SM-102: heptadecan-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate	Trisodium citrate dihydrate
	Sodium chloride	Tromethamine	Sodium chloride
	Monobasic potassium phosphate	Tromethamine hydrochloride	Ethanol
	Potassium chloride	Acetic acid	
	Dibasic sodium phosphate dihydrate	Sodium acetate	
	Sucrose	Sucrose	

Adapted from <https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>

